IL281719B - 4'-phenyl-2-oxospiro]indoline-3,3'-pyrrolidine]-5' carboxamide derivatives as mdm2 protein complexes - Google Patents

4'-phenyl-2-oxospiro]indoline-3,3'-pyrrolidine]-5' carboxamide derivatives as mdm2 protein complexes

Info

Publication number
IL281719B
IL281719B IL281719A IL28171921A IL281719B IL 281719 B IL281719 B IL 281719B IL 281719 A IL281719 A IL 281719A IL 28171921 A IL28171921 A IL 28171921A IL 281719 B IL281719 B IL 281719B
Authority
IL
Israel
Prior art keywords
oxospiro
indoline
pyrrolidine
phenyl
carboxamide derivatives
Prior art date
Application number
IL281719A
Other languages
English (en)
Hebrew (he)
Other versions
IL281719A (en
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of IL281719A publication Critical patent/IL281719A/en
Publication of IL281719B publication Critical patent/IL281719B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL281719A 2018-10-08 2021-03-22 4'-phenyl-2-oxospiro]indoline-3,3'-pyrrolidine]-5' carboxamide derivatives as mdm2 protein complexes IL281719B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862742627P 2018-10-08 2018-10-08
PCT/US2019/054913 WO2020076660A1 (en) 2018-10-08 2019-10-07 Small molecule mdm2 protein degraders

Publications (2)

Publication Number Publication Date
IL281719A IL281719A (en) 2021-05-31
IL281719B true IL281719B (en) 2022-06-01

Family

ID=68343478

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281719A IL281719B (en) 2018-10-08 2021-03-22 4'-phenyl-2-oxospiro]indoline-3,3'-pyrrolidine]-5' carboxamide derivatives as mdm2 protein complexes

Country Status (12)

Country Link
US (2) US11046703B2 (zh)
EP (1) EP3863720A1 (zh)
JP (1) JP2022504541A (zh)
KR (1) KR20210072043A (zh)
CN (1) CN112912143A (zh)
AU (1) AU2019356772A1 (zh)
BR (1) BR112021006647A2 (zh)
CA (1) CA3112591A1 (zh)
IL (1) IL281719B (zh)
MX (1) MX2021003999A (zh)
SG (1) SG11202103282YA (zh)
WO (1) WO2020076660A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103282YA (en) * 2018-10-08 2021-04-29 Univ Michigan Regents Small molecule mdm2 protein degraders
WO2021051034A1 (en) 2019-09-13 2021-03-18 Biotheryx, Inc. Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN114853731A (zh) * 2021-02-04 2022-08-05 上海长森药业有限公司 一种双功能mdm2蛋白降解剂，及其制备方法、药物组合物和应用
MX2024003076A (es) * 2021-09-13 2024-03-27 Astrazeneca Ab Compuestos espirociclicos.
US20230233546A1 (en) * 2021-12-15 2023-07-27 Kymera Therapeutics, Inc. Methods of treating cancer
WO2023239697A1 (en) * 2022-06-06 2023-12-14 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
WO2024078370A1 (zh) * 2022-10-13 2024-04-18 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3'-吡咯烷]结构的小分子化合物
WO2024197219A1 (en) * 2023-03-22 2024-09-26 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (pt) 1980-09-24 1982-08-24 Cetus Corp Processo e sonda de diagnostico
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
DE60225719T2 (de) 2001-12-18 2009-04-23 F. Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
DE60227108D1 (de) 2001-12-18 2008-07-24 Hoffmann La Roche Cis-imidazoline als mdm2-hemmer
US7514579B2 (en) 2002-06-13 2009-04-07 Johns Hopkins University Boronic chalcone derivatives and uses thereof
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
WO2004073615A2 (en) 2003-02-13 2004-09-02 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Deazaflavin compounds and methods of use thereof
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
WO2005063774A1 (en) 2003-12-22 2005-07-14 Johns Hopkins University Boronic acid aryl analogs
US8598127B2 (en) 2004-04-06 2013-12-03 Korea Research Institute Of Bioscience & Biotechnology Peptides for inhibiting MDM2 function
KR20080027969A (ko) 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
CA2599476A1 (en) 2005-03-16 2006-09-21 F. Hoffmann-La Roche Ag Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
CN101605798A (zh) 2006-12-14 2009-12-16 第一三共株式会社 咪唑并噻唑衍生物
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
CA2780547C (en) 2009-11-12 2015-02-03 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
EA201390682A1 (ru) 2010-11-12 2014-01-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Спирооксиндольные антагонисты mdm2
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
EP2922861A4 (en) 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
CA2979070A1 (en) * 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US10759808B2 (en) * 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CN109415336B (zh) 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
AU2017370694A1 (en) * 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
SG11202103282YA (en) * 2018-10-08 2021-04-29 Univ Michigan Regents Small molecule mdm2 protein degraders

Also Published As

Publication number Publication date
US11046703B2 (en) 2021-06-29
CA3112591A1 (en) 2020-04-16
US20200109149A1 (en) 2020-04-09
AU2019356772A1 (en) 2021-04-01
IL281719A (en) 2021-05-31
EP3863720A1 (en) 2021-08-18
WO2020076660A1 (en) 2020-04-16
BR112021006647A2 (pt) 2021-07-13
SG11202103282YA (en) 2021-04-29
JP2022504541A (ja) 2022-01-13
KR20210072043A (ko) 2021-06-16
MX2021003999A (es) 2021-06-23
CN112912143A (zh) 2021-06-04
US20210309666A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
IL281719B (en) 4'-phenyl-2-oxospiro]indoline-3,3'-pyrrolidine]-5' carboxamide derivatives as mdm2 protein complexes
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物
MA47500A (fr) Dérivés de pyrrolo [1,2-b]pyridazine
DK3134403T3 (en) 1h-pyrrolo[2,3-c]pyridin-7(6h)-on og pyrazolo[3,4-c]pyridin-7(6h)-on som inhibitorer af bet-proteiner
IL261231B (en) Mcl-1 (r)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2h)-one inhibitors
EP3543242A4 (en) 8,9-DIHYDROIMIDAZOLE [1,2-A] PYRIMIDO [5,4-E] PYRIMIDINE-5 (6H) KETONE COMPOUND
IL287390A (en) h4-Pyrrolo [2,3-c]pyridin-4-one compounds
ZA201700110B (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
SG11202100338PA (en) Imidazo[1,2-b]pyridazines as trk inhibitors
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
IL280661A (en) PYRROLO[2,3-B]PYRIDINE is mutated at position 4 as ERBB regulators that are useful in cancer therapy
EP3660019C0 (en) 7H-PYRAZOLO[3,4-D]TRIAZINE-2-OXIDES AS EXPLOSIVES
HK1259613A1 (zh) 新型5h-吡咯並[2，3-d]嘧啶-6(7h)-酮衍生物
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
IL269215A (en) Disubstituted imidazole[4,5-C]quinoline derivatives
EP3851439A4 (en) BTK INHIBITOR CONTAINING FURO[3,4-B]PYRROLE
DK3740492T3 (da) 1,2,3',5'-tetrahydro-2'h-spiro[indol-3,1¿-pyrrol[3,4-c]pyrrol]-2,3'-dionforbindelser som terapeutiske midler til aktivering af tp53